SCH-39370| CAS#115406-23-0 | neutral metalloendopeptidase inhibitor

MedKoo Cat#: 526312 | Name: SCH-39370

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SCH-39370 is a potent and specific inhibitor of neutral metalloendopeptidase (NEP).

Chemical Structure

SCH-39370

CAS#115406-23-0

Theoretical Analysis

MedKoo Cat#: 526312

Name: SCH-39370

CAS#: 115406-23-0

Chemical Formula: C22H26N2O6

Exact Mass: 414.1791

Molecular Weight: 414.46

Elemental Analysis: C, 63.76; H, 6.32; N, 6.76; O, 23.16

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

SCH-39370; SCH 39370; SCH39370.

IUPAC/Chemical Name

(S)-2-(((S)-1-(((S)-2-carboxy-2-hydroxyethyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-4-phenylbutanoic acid

InChi Key

AWBZAFHNXGOVMY-FHWLQOOXSA-N

InChi Code

InChI=1S/C22H26N2O6/c25-19(14-20(26)27)24-21(28)18(13-16-9-5-2-6-10-16)23-17(22(29)30)12-11-15-7-3-1-4-8-15/h1-10,17-19,23,25H,11-14H2,(H,24,28)(H,26,27)(H,29,30)/t17-,18-,19-/m0/s1

SMILES Code

O=C(O)C[C@H](O)NC([C@H](CC1=CC=CC=C1)N[C@H](C(O)=O)CCC2=CC=CC=C2)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 414.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Chappell MC, Allred AJ, Ferrario CM. Pathways of angiotensin-(1-7) metabolism in the kidney. Nephrol Dial Transplant. 2001;16 Suppl 1:22-6. Review. PubMed PMID: 11369816. 2: Iyer SN, Averill DB, Chappell MC, Yamada K, Allred AJ, Ferrario CM. Contribution of angiotensin-(1-7) to blood pressure regulation in salt-depleted hypertensive rats. Hypertension. 2000 Sep;36(3):417-22. PubMed PMID: 10988275. 3: Chappell MC, Gomez MN, Pirro NT, Ferrario CM. Release of angiotensin-(1-7) from the rat hindlimb: influence of angiotensin-converting enzyme inhibition. Hypertension. 2000 Jan;35(1 Pt 2):348-52. PubMed PMID: 10642323. 4: Hämäläinen KM, Ranta VP, Auriola S, Urtti A. Enzymatic and permeation barrier of [D-Ala(2)]-Met-enkephalinamide in the anterior membranes of the albino rabbit eye. Eur J Pharm Sci. 2000 Jan;9(3):265-70. PubMed PMID: 10594383. 5: Kokkonen JO, Kuoppala A, Saarinen J, Lindstedt KA, Kovanen PT. Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase. Circulation. 1999 Apr 20;99(15):1984-90. PubMed PMID: 10209002. 6: Kousides M, Story ME, Pennefather JN. Endopeptidase 24.11 inhibition does not modify uterotonic effects of endothelins in rat uterus. Peptides. 1998;19(9):1585-93. PubMed PMID: 9864067. 7: Ranta VP, Hämäläinen KM, Auriola S, Urtti A. Gradient high-performance liquid chromatographic analysis of enkephalin peptides, their metabolites, and enzyme inhibitors using combined ultraviolet and electrochemical detection II. Application to ocular permeability studies in vitro. J Chromatogr B Biomed Sci Appl. 1998 May 8;709(1):1-10. PubMed PMID: 9653920. 8: Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension. 1998 Jan;31(1 Pt 2):356-61. PubMed PMID: 9453328. 9: Fisher L, Pennefather JN. Potencies of agonists acting at tachykinin receptors in the oestrogen-primed rat uterus: effects of peptidase inhibitors. Eur J Pharmacol. 1997 Sep 24;335(2-3):221-6. PubMed PMID: 9369377. 10: Tomoda F, Lew RA, Smith AI, Madden AC, Evans RG. Role of bradykinin receptors in the renal effects of inhibition of angiotensin converting enzyme and endopeptidases 24.11 and 24.15 in conscious rabbits. Br J Pharmacol. 1996 Sep;119(2):365-73. PubMed PMID: 8886422; PubMed Central PMCID: PMC1915843. 11: Lew RA, Tomoda F, Evans RG, Lakat L, Boublik JH, Pipolo LA, Smith AI. Synthetic inhibitors of endopeptidase EC 3.4.24.15: potency and stability in vitro and in vivo. Br J Pharmacol. 1996 Jul;118(5):1269-77. PubMed PMID: 8818353; PubMed Central PMCID: PMC1909604. 12: Rademaker MT, Fitzpatrick MA, Charles CJ, Richards AM, Nicholls MG, Espiner EA, Sybertz E. Comparison of chronic neutral endopeptidase inhibition and furosemide in an ovine model of heart failure. J Cardiovasc Pharmacol. 1996 Mar;27(3):439-46. PubMed PMID: 8907807. 13: Sajid M, Isaac RE. Identification and properties of a neuropeptide-degrading endopeptidase (neprilysin) of Ascaris suum muscle. Parasitology. 1995 Dec;111 ( Pt 5):599-608. PubMed PMID: 8559593. 14: Charles CJ, Espiner EA, Richards AM, Sybertz EJ. Endopeptidase inhibition in angiotensin-induced hypertension. Effect of SCH 39370 in sheep. Hypertension. 1995 Jul;26(1):89-94. PubMed PMID: 7607738. 15: Sirviö ML, Saijonmaa O, Metsärinne K, Fyhrquist F. Degradation of endothelin-1 by extracts of rat lung, kidney, and liver. Regul Pept. 1995 Feb 14;55(3):219-25. PubMed PMID: 7761621. 16: Lamango NS, Isaac RE. Metabolism of insect neuropeptides: properties of a membrane-bound endopeptidase from heads of Musca domestica. Insect Biochem Mol Biol. 1993 Oct;23(7):801-8. PubMed PMID: 8374613. 17: Yandle T, Richards M, Smith M, Charles C, Livesey J, Espiner E. Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors. Clin Chem. 1992 Sep;38(9):1785-91. PubMed PMID: 1526015. 18: Kanazawa M, Casley DJ, Sybertz EJ, Haslanger MF, Johnston CI. Localization and characterization of neutral metalloendopeptidase (EC 3.4.24.11), the degradative enzyme for atrial natriuretic peptide, in rat kidney using a radioiodinated neutral metalloendopeptidase inhibitor. J Pharmacol Exp Ther. 1992 Jun;261(3):1231-7. PubMed PMID: 1534841. 19: Murohara Y, Johnston CI. Effect of neutral endopeptidase inhibitor in rats with congestive heart failure. Clin Exp Pharmacol Physiol. 1992 May;19(5):380-3. PubMed PMID: 1325886. 20: Fitzpatrick MA, Rademaker MT, Charles CJ, Yandle TG, Espiner EA, Ikram H, Sybertz E. Acute hemodynamic, hormonal, and renal effects of neutral endopeptidase inhibition in ovine heart failure. J Cardiovasc Pharmacol. 1992 Apr;19(4):635-40. PubMed PMID: 1380608. .